Phase 3 Sickle Cell Disease Trial, Recruiting NCT05392894 Sponsor: King's College Hospital NHS Trust Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Phase 3 Sickle Cell Disease Trial, Recruiting

NCT05392894
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have a half-matched (haploidentical) family donor available — this means a donor who shares about half of their tissue type markers with you, such as a parent, child, or sibling
  • You have sickle cell disease (SCD) that is considered severe, meaning at least one of the following applies to you:
    • You have had a stroke or a serious neurological event lasting more than 24 hours
    • You have had 2 or more acute chest crises within a 2-year period, even while receiving the best available treatment
    • You have had 3 or more severe pain crises per year over a 2-year period, even while receiving the best available treatment
    • You need regular blood transfusions (8 or more per year) to prevent complications
    • You need transfusions but have developed antibodies that make it very difficult to find compatible blood, or you have a very rare blood type
    • You need hydroxyurea or transfusions for your SCD but cannot tolerate either treatment due to serious side effects
    • You have lasting damage to organs caused by SCD, such as blood vessel or liver problems (confirm with trial site)
  • Your general health is good enough to safely undergo a stem cell transplant, including your heart, lungs, kidneys, and liver all meeting certain minimum levels of function (confirm specific thresholds with trial site)
  • You are able and willing to give written consent to take part in the trial

Who may not be able to join:

  • You have a fully matched sibling donor available
  • You have already had a bone marrow transplant in the past
  • You are currently pregnant or breastfeeding
  • You are able to father or become pregnant and are not willing to use effective contraception during the trial
  • You have significant antibodies in your blood that are directed against your donor's tissue type, which could cause problems with the transplant (confirm with trial site)
  • You have HIV, or currently active Hepatitis B or Hepatitis C infection
  • You have an infection (bacterial, fungal, or viral) that is not currently under control
  • You have taken part in another clinical intervention trial within the last three months
  • You have another existing health condition that your doctor believes would significantly increase the risks of having this type of transplant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ann-Marie Murtagh, King's College Hospitals NHS Foundation Trust

Phone: +44 20 3299 3730

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
King's College Hospital NHS Trust
Registry
ClinicalTrials.gov
Start date
23 February 2023
Est. completion
1 March 2027

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Treatment failure or mortality

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov